Indications And Dose
Raised intra-ocular pressure in open-angle glaucoma | Ocular hypertension ▶TO THE EYE ▶Adult: Apply once daily, to be administered preferably in the evening
Source page 1272
Loading InternPractice…
Individual generic drug information
Extracted information for Bimatoprost only.
Raised intra-ocular pressure in open-angle glaucoma | Ocular hypertension ▶TO THE EYE ▶Adult: Apply once daily, to be administered preferably in the evening
Source page 1272
Angle-closure glaucoma (no experience of use) . aphakia. asthma. chronic obstructive pulmonary disease . compromised respiratory function. congenital glaucoma (no experience of use). contact lens wearers. history of significant ocular viral infections. inflammatory ocular conditions (no experience of use). narrow-angle glaucoma Eye (no experience of use). neovascular glaucoma (no experience of use). predisposition to bradycardia. predisposition to hypotension. pseudophakia with torn posterior lens capsule or anterior chamber lenses. risk factors for cystoid macular oedema. risk factors for iritis. risk factors for uveitis
Source page 1272
Although multi-dose bimatoprost eye drops commonly contain preservatives, preservative-free unit dose vials may be available.
Source page 1272
LUMIGAN ® Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (March 2013) that bimatoprost 300 micrograms/mL preservative- free eye drops (Lumigan ® single-dose eye drops) are accepted for restricted use within NHS Scotland for the reduction of elevated intra-ocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers) in adults who have proven sensitivity to benzalkonium chloride.
Source page 1272
Extracted information for Bimatoprost only.
▶Common or very common Dry eye. eye discolouration. eye discomfort. eye disorders. eye inflammation. headache. hypertension. hypertrichosis. skin reactions. vision disorders ▶Uncommon Asthenia. dizziness. madarosis. nausea. retinal haemorrhage ▶Frequency not known Asthma. bradycardia. dyspnoea. hypotension. reactivation of infection
Source page 1272
Manufacturer advises use only if potential benefit outweighs risk.
Source page 1272
Manufacturer advises avoid—present in milk in animal studies.
Source page 1272
Manufacturer advises use with caution in moderate-to-severe impairment—no information available.
Source page 1272
Use with caution—no information available.
Source page 1272
Extracted information for Bimatoprost only.
There can be variation in the licensing of different medicines containing the same drug. Eye drops EXCIPIENTS: May contain Benzalkonium chloride ▶Bimatoprost (Non-proprietary) Bimatoprost 100 microgram per 1 ml Bimatoprost 100micrograms/ml eye drops | 3 ml P £14.05 DT = £12.88 | 9 ml P £29.86 Bimatoprost 300 microgram per 1 ml Bimatoprost 300micrograms/ml eye drops | 3 ml P £12.36 DT = £11.85 ▶Eyreida (Aspire Pharma Ltd) Bimatoprost 300 microgram per 1 ml Eyreida 0.3mg/ml eye drops | 3 ml P £11.71 DT = £11.71 ▶Lumigan (Allergan Ltd) Bimatoprost 100 microgram per 1 ml Lumigan 100micrograms/ml eye drops | 3 ml P £11.71 DT = £12.88 | 9 ml P £35.13 Bimatoprost 300 microgram per 1 ml Lumigan 300micrograms/ml eye drops 0.4ml unit dose | 30 unit dose P £13.75 DT = £13.75
Source page 1272
Extracted information for Bimatoprost only.
Changes to eye colour Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.
Source page 1272
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
Apply once daily, to be administered preferably
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 1272